Literature DB >> 28698066

Nasal nanovaccines.

B Bernocchi1, R Carpentier2, D Betbeder3.   

Abstract

Nasal administration of vaccines is convenient for the potential stimulation of mucosal and systemic immune protection. Moreover the easy accessibility of the intranasal route renders it optimal for pandemic vaccination. Nanoparticles have been identified as ideal delivery systems and adjuvants for vaccine application. Heterogeneous protocols have been used for animal studies. This complicates the understanding of the formulation influence on the immune response and the comparison of the different nanoparticles approaches developed. Moreover anatomical and immunological differences between rodents and humans provide an additional hurdle in the rational development of nasal nanovaccines. This review will give a comprehensive expertise of the state of the art in nasal nanovaccines in animals and humans focusing on the nanomaterial used.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  NALT; Nanoparticles; Nasal vaccines; Vaccine delivery

Mesh:

Substances:

Year:  2017        PMID: 28698066     DOI: 10.1016/j.ijpharm.2017.07.012

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  14 in total

1.  Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses.

Authors:  Youhui Si; Qiaomu Tian; Fan Zhao; Sean H Kelly; Lucas S Shores; Daniel F Camacho; Anne I Sperling; Michael S Andrade; Joel H Collier; Anita S Chong
Journal:  Sci Adv       Date:  2020-08-07       Impact factor: 14.136

Review 2.  Mucosal immunoglobulins of teleost fish: A decade of advances.

Authors:  Irene Salinas; Álvaro Fernández-Montero; Yang Ding; J Oriol Sunyer
Journal:  Dev Comp Immunol       Date:  2021-03-27       Impact factor: 3.605

Review 3.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

4.  Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to M. Tuberculosis Infection.

Authors:  Antonella Riccomi; Giovanni Piccaro; Dennis Christensen; Carla Palma; Peter Andersen; Silvia Vendetti
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 5.  Chitosan Nanoparticle Based Mucosal Vaccines Delivered Against Infectious Diseases of Poultry and Pigs.

Authors:  Sankar Renu; Gourapura J Renukaradhya
Journal:  Front Bioeng Biotechnol       Date:  2020-11-13

Review 6.  Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit.

Authors:  Bharti Mangla; Shamama Javed; Muhammad H Sultan; Waquar Ahsan; Geeta Aggarwal; Kanchan Kohli
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

Review 7.  Recent Advances and Future Perspectives in Polymer-Based Nanovaccines.

Authors:  Natassa Pippa; Maria Gazouli; Stergios Pispas
Journal:  Vaccines (Basel)       Date:  2021-05-26

8.  Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.

Authors:  Valentina Bernasconi; Beatrice Bernocchi; Liang Ye; Minh Quan Lê; Ajibola Omokanye; Rodolphe Carpentier; Karin Schön; Xavier Saelens; Peter Staeheli; Didier Betbeder; Nils Lycke
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

Review 9.  The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection.

Authors:  Oreste Gallo; Luca Giovanni Locatello; Alessio Mazzoni; Luca Novelli; Francesco Annunziato
Journal:  Mucosal Immunol       Date:  2020-11-26       Impact factor: 7.313

Review 10.  Development of Pharmaceutical Nanomedicines: From the Bench to the Market.

Authors:  Abdulrahman A Halwani
Journal:  Pharmaceutics       Date:  2022-01-03       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.